Pitfall in chemotherapy for ovarian cancer

Toshiharu Kamura, YoungTae Kim

Research output: Contribution to journalReview article

Abstract

Concerning the biological properties of recurrent ovarian cancer, other than drug resistance, we revealed that the expressions of mutant p53 and CD44v6 genes were significantly greater in recurrent ovarian cancer than in those of its primary counterpart. These findings suggest that chemotherapeutic agents may modify some biological characteristics of cancer by altering gene expressions. The biological behavior concerning the metastatic potential of a recurrent disease must be elucidated in order to develop an optional treatment regimen against recurrent tumors. Therefore, we established in-vivo cisplatin-resistant cell lines by repeated administration, in order to find a more suitable model for reflecting the biological aggressiveness of clinically recurrent ovarian cancer following chemotherapy. Chemotherapeutic agents have given a substantial advantage to cancer patients. It must be borne in mind that the cancer cells surviving following chemotherapy possibly present different biological properties from primary cancer cells, and that these properties might be developed by the chemotherapeutic agents.

Original languageEnglish
Pages (from-to)779-782
Number of pages4
JournalYonsei Medical Journal
Volume43
Issue number6
DOIs
Publication statusPublished - 2002 Jan 1

Fingerprint

Ovarian Neoplasms
Drug Therapy
Neoplasms
Biological Models
Neoplasm Genes
p53 Genes
Drug Resistance
Cisplatin
Gene Expression
Cell Line
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kamura, Toshiharu ; Kim, YoungTae. / Pitfall in chemotherapy for ovarian cancer. In: Yonsei Medical Journal. 2002 ; Vol. 43, No. 6. pp. 779-782.
@article{20b01fc7a11c40aab88c152bd51e03d7,
title = "Pitfall in chemotherapy for ovarian cancer",
abstract = "Concerning the biological properties of recurrent ovarian cancer, other than drug resistance, we revealed that the expressions of mutant p53 and CD44v6 genes were significantly greater in recurrent ovarian cancer than in those of its primary counterpart. These findings suggest that chemotherapeutic agents may modify some biological characteristics of cancer by altering gene expressions. The biological behavior concerning the metastatic potential of a recurrent disease must be elucidated in order to develop an optional treatment regimen against recurrent tumors. Therefore, we established in-vivo cisplatin-resistant cell lines by repeated administration, in order to find a more suitable model for reflecting the biological aggressiveness of clinically recurrent ovarian cancer following chemotherapy. Chemotherapeutic agents have given a substantial advantage to cancer patients. It must be borne in mind that the cancer cells surviving following chemotherapy possibly present different biological properties from primary cancer cells, and that these properties might be developed by the chemotherapeutic agents.",
author = "Toshiharu Kamura and YoungTae Kim",
year = "2002",
month = "1",
day = "1",
doi = "10.3349/ymj.2002.43.6.779",
language = "English",
volume = "43",
pages = "779--782",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "6",

}

Pitfall in chemotherapy for ovarian cancer. / Kamura, Toshiharu; Kim, YoungTae.

In: Yonsei Medical Journal, Vol. 43, No. 6, 01.01.2002, p. 779-782.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pitfall in chemotherapy for ovarian cancer

AU - Kamura, Toshiharu

AU - Kim, YoungTae

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Concerning the biological properties of recurrent ovarian cancer, other than drug resistance, we revealed that the expressions of mutant p53 and CD44v6 genes were significantly greater in recurrent ovarian cancer than in those of its primary counterpart. These findings suggest that chemotherapeutic agents may modify some biological characteristics of cancer by altering gene expressions. The biological behavior concerning the metastatic potential of a recurrent disease must be elucidated in order to develop an optional treatment regimen against recurrent tumors. Therefore, we established in-vivo cisplatin-resistant cell lines by repeated administration, in order to find a more suitable model for reflecting the biological aggressiveness of clinically recurrent ovarian cancer following chemotherapy. Chemotherapeutic agents have given a substantial advantage to cancer patients. It must be borne in mind that the cancer cells surviving following chemotherapy possibly present different biological properties from primary cancer cells, and that these properties might be developed by the chemotherapeutic agents.

AB - Concerning the biological properties of recurrent ovarian cancer, other than drug resistance, we revealed that the expressions of mutant p53 and CD44v6 genes were significantly greater in recurrent ovarian cancer than in those of its primary counterpart. These findings suggest that chemotherapeutic agents may modify some biological characteristics of cancer by altering gene expressions. The biological behavior concerning the metastatic potential of a recurrent disease must be elucidated in order to develop an optional treatment regimen against recurrent tumors. Therefore, we established in-vivo cisplatin-resistant cell lines by repeated administration, in order to find a more suitable model for reflecting the biological aggressiveness of clinically recurrent ovarian cancer following chemotherapy. Chemotherapeutic agents have given a substantial advantage to cancer patients. It must be borne in mind that the cancer cells surviving following chemotherapy possibly present different biological properties from primary cancer cells, and that these properties might be developed by the chemotherapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=0036949735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036949735&partnerID=8YFLogxK

U2 - 10.3349/ymj.2002.43.6.779

DO - 10.3349/ymj.2002.43.6.779

M3 - Review article

VL - 43

SP - 779

EP - 782

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 6

ER -